Tharimmune, Inc. (NASDAQ:THAR) Sees Significant Drop in Short Interest

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 52,700 shares, a decline of 54.3% from the April 30th total of 115,400 shares. Based on an average daily trading volume, of 134,200 shares, the short-interest ratio is presently 0.4 days. Approximately 2.0% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Virtu Financial LLC bought a new stake in Tharimmune, Inc. (NASDAQ:THAR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned 1.11% of Tharimmune at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.16% of the company’s stock.

Tharimmune Stock Up 0.7%

Shares of THAR stock traded up $0.01 during trading hours on Friday, reaching $1.49. 22,725 shares of the stock traded hands, compared to its average volume of 376,981. Tharimmune has a 1-year low of $0.95 and a 1-year high of $6.39. The business has a fifty day moving average price of $1.33 and a 200 day moving average price of $1.74. The firm has a market capitalization of $3.96 million, a PE ratio of -0.19 and a beta of 1.11.

Tharimmune (NASDAQ:THAR) last announced its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.15).

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).